Molecular Partners (MOLN) Competitors

Molecular Partners (NASDAQ:MOLN) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Is MOLN or IMTX more profitable?

Immatics has a net margin of -47.94% compared to Molecular Partners' net margin of -1,043.01%. Immatics' return on equity of -15.90% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	-1,043.01%	-39.31%	-35.46%
Immatics	-47.94%	-15.90%	-9.38%

Do insiders & institutionals have more ownership in MOLN or IMTX?

26.5% of Molecular Partners shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more volatility and risk, MOLN or IMTX?

Molecular Partners has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Immatics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Does the MarketBeat Community favor MOLN or IMTX?

Immatics received 18 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 75.61% of users gave Immatics an outperform vote while only 48.15% of users gave Molecular Partners an outperform vote.

Company	Underperform	Outperform
Molecular Partners	Outperform Votes 13 48.15%	Underperform Votes 14 51.85%
Immatics	Outperform Votes 31 75.61%	Underperform Votes 10 24.39%

Which has better valuation & earnings, MOLN or IMTX?

Molecular Partners has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$2.23M	71.27	-$69.04M	-$1.92	-2.05
Immatics	$144.15M	4.27	-$104.98M	-$0.17	-29.79

Does the media favor MOLN or IMTX?

In the previous week, Immatics had 2 more articles in the media than Molecular Partners. MarketBeat recorded 12 mentions for Immatics and 10 mentions for Molecular Partners. Immatics' average media sentiment score of 1.31 beat Molecular Partners' score of 0.32 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer MOLN or IMTX?

Molecular Partners currently has a consensus price target of $12.00, indicating a potential upside of 204.57%. Immatics has a consensus price target of $17.00, indicating a potential upside of 235.70%. Given Immatics' higher possible upside, analysts clearly believe Immatics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Immatics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Summary

Immatics beats Molecular Partners on 12 of the 18 factors compared between the two stocks.